Vitrafy's No-Wash Frozen Platelet Technology Achieves 94% Recovery Rate in US Army Validation Study
Key Insights
Vitrafy Life Sciences (search)' cryopreservation technology achieved 94% mean post-thaw platelet recovery in an independent Phase 2 study led by the US Army Institute of Surgical Research.
The no-wash 3% DMSO protocol outperformed wash-based alternatives and demonstrated superior clot strength with nearly twice the platelet receptor retention.
This validation represents the largest blood platelet testing exercise using Vitrafy's system and positions the company for FDA medical device registration in the first half of 2027.
Vitrafy Life Sciences (search) has achieved a significant breakthrough in platelet preservation technology, with an independent Phase 2 in vitro study led by the United States Army Institute of Surgical Research (search) (USAISR (search)) validating the company's cryopreservation ecosystem as capable of delivering near-fresh platelet quality at commercial volumes.
The Texas-based study tested apheresis platelets from 20 donors across three cryopreservation protocols and found that a no-wash 3% dimethyl sulfoxide (DMSO) protocol produced a mean post-thaw platelet recovery of 94%, significantly outperforming a 6% DMSO wash protocol at 84% and a trehalose no-wash protocol at 78.9%.
Superior Functional Performance
The Phase 2 study assessed not only recovery rates but also functional performance through clot strength and retention of key platelet surface receptors (search) that support clotting. The 3% DMSO no-wash formulation demonstrated superior clot-forming strength and retained nearly twice the level of key platelet receptors after thawing compared to the wash protocol.
This functional data is particularly significant as it demonstrates that the preserved platelets maintain their therapeutic efficacy, not just their quantity. All tested protocols exceeded current regulatory and quality guidelines for platelet use, with results meeting or exceeding commonly accepted liquid-stored fresh platelet quality metrics.
Operational Advantages of No-Wash Technology
The operational implications of a no-wash solution represent a paradigm shift in platelet preservation. Traditional wash-based protocols require centrifugation and reconstitution with freshly thawed plasma, using specialized equipment and trained personnel, thereby restricting their use to specialized settings.
In contrast, a decentralized no-wash protocol that delivers near-fresh post-thaw quality could enable stockpiling for event preparedness and extend access to rural hospitals and battlefield and emergency-response settings, where the current platelet supply is logistically constrained.
Military and Clinical Impact
Dr. Kristin Reddoch Cardenas, the USAISR (search) research lead, emphasized the clinical significance of the findings: "The ability to effectively utilize frozen platelets represents a vital advancement in addressing critical, growing needs across both civilian and military trauma (search) response. We are proud of the scientific achievements resulting from this Phase II work and look forward to developing these findings into a peer-reviewed publication."
The Phase 2 program represents the largest blood platelet testing exercise completed to date using the Vitrafy system and provides US military-authorized validation that cryopreserved platelets can be produced at scale while meeting stringent quality requirements.
Regulatory Pathway and Commercial Prospects
Vitrafy Managing Director and CEO Brent Owens highlighted the regulatory significance of the validation: "The final Phase II report from USAISR (search) delivers independent validation that our decentralized, no-wash platelet preservation platform exceeds regulatory and quality guidelines on every meaningful measure. Across 20 donors and at commercial volumes, we achieved 94% post-thaw recovery with superior clot strength and receptor retention — results that speak for themselves."
The company is progressing toward FDA medical device registration in the first half of FY2027 and plans to present the Phase II findings with USAISR (search) at international scientific conferences over the coming months. With no commercially available frozen platelet product currently on the market, Vitrafy's technology could address a significant market gap with a differentiated offering supported by independent military validation.